Sign inJoin waitlistJoin the waitlist

RH

Robert Holloway

Co-Medical Director, Gynecologic Oncology · AdventHealth Orlando

Credentials: · · · ·

History

Gynecologic Oncology · AdventHealth Orlando
Present
AdventHealth Florida
Present
University of Central Florida College of Medicine
Present

Georgetown University Hospital
1989–1992
MedStar Georgetown University Hospital
1985–1989
Vanderbilt University School of Medicine
1979–1983

Research

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet · 2017 · 1,408 citations
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
JAMA Oncology · 2019 · 468 citations
Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations
Review · Gynecologic Oncology · 2017 · First of 9 authors · Corresponding · 297 citations

David O'Malley
17 papers
NF
Neil Finkler
15 papers
James Kendrick
13 papers · 1 as a fellow
CA
Carol Aghajanian
12 papers
NM
Nathalie McKenzie
12 papers
GB
Glenn Bigsby
11 papers
RC
Robert Coleman
11 papers
Thomas Herzog
11 papers
Elizabeth Swisher
9 papers
JO
James Orr
9 papers
LB
Lorna Brudie
9 papers
Deborah Armstrong
7 papers

Clinical trials

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Principal investigator · Recruiting · Phase 3
Genelux Corporation
2022–2027
Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG
Principal investigator · Completed
AdventHealth
2012–2015
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Principal investigator · Terminated · Phase 2
Facet Biotech
2007–2008